BRIXELLE Trademark

Trademark Overview


On Tuesday, December 1, 2020, a trademark application was filed for BRIXELLE with the United States Patent and Trademark Office. The USPTO has given the BRIXELLE trademark a serial number of 79302745. The federal status of this trademark filing is REGISTERED as of Tuesday, August 23, 2022. This trademark is owned by Bilix Co., Ltd.. The BRIXELLE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical agents affecting sensory organs; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for peripheral nervous system; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for the treatment of viral diseases; pharmaceuticals for the treatment of erectile dysfunction; vaccines; anti-inflammatory preparations; medicines for intestinal disorders; pharmaceutical agents affecting digestive org...
brixelle

General Information


Serial Number79302745
Word MarkBRIXELLE
Filing DateTuesday, December 1, 2020
Status700 - REGISTERED
Status DateTuesday, August 23, 2022
Registration Number6822946
Registration DateTuesday, August 23, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 7, 2022

Trademark Statements


Goods and ServicesPharmaceutical agents affecting sensory organs; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for peripheral nervous system; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for the treatment of viral diseases; pharmaceuticals for the treatment of erectile dysfunction; vaccines; anti-inflammatory preparations; medicines for intestinal disorders; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; ophthalmic preparations; biological preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical agents for epidermis; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; enzymes for medical purposes; diagnostic preparations for medical or veterinary purposes; immunoassay reagents for medical use; medical reagents for testing genetic identity for medical purposes; pharmaceutical preparations for neurological disease; pharmaceutical preparations for inflammatory diseases; pharmaceutical preparations for ocular and intraocular surgery; pharmaceutical preparations for rare autoimmune diseases in the nature of autoimmune lymphoproliferative syndrome, lupus, and multiple sclerosis; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutical products for the prevention and treatment of rare genetic diseases affecting red blood cells; medicated ointments for treating dermatological conditions; antibiotic ointments; mentholated ointment for medical use; anti-inflammatory ointments; chemical reagents for purposes of medical diagnosis; diagnostic preparations for diagnosing inflammatory diseases; diagnostic radiopharmaceutical preparations; pharmaceutical and biological preparations for use in diagnosis, namely, for use as ultrasound and X-ray contrast reagents; human vaccine preparations; pharmaceutical preparations acting on the central nervous system; preparations for the treatment of asthma; medicines for dental purposes; dermatological pharmaceutical products; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; antibiotics; anti-cancer preparations; tumor suppressing agents; pharmaceutical products for treating respiratory diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 22, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBilix Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressKR

Party NameBilix Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKR

Party NameBilix Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events


Event DateEvent Description
Tuesday, December 27, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, December 1, 2022FINAL DISPOSITION NOTICE SENT TO IB
Thursday, December 1, 2022FINAL DISPOSITION PROCESSED
Wednesday, November 23, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 23, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, August 23, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, July 12, 2022NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, June 22, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, June 22, 2022NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, June 7, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 7, 2022PUBLISHED FOR OPPOSITION
Wednesday, May 18, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, May 2, 2022ASSIGNED TO LIE
Friday, April 29, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 28, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 27, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 27, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, October 29, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, October 29, 2021FINAL REFUSAL E-MAILED
Friday, October 29, 2021FINAL REFUSAL WRITTEN
Thursday, September 30, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 30, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 30, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 17, 2021REFUSAL PROCESSED BY IB
Monday, April 26, 2021NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, April 26, 2021REFUSAL PROCESSED BY MPU
Friday, April 23, 2021NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, April 22, 2021NON-FINAL ACTION WRITTEN
Wednesday, April 21, 2021ASSIGNED TO EXAMINER
Tuesday, January 26, 2021APPLICATION FILING RECEIPT MAILED
Friday, January 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, January 21, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB